These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18276097)

  • 1. [Use of a program-specific website to disseminate data on antimicrobial susceptibility of clinical isolates from the Tigecycline Evaluation and Surveillance Trial (TEST)].
    Leclercq R; Goulenok C; Loncle-Provot V
    Med Mal Infect; 2008 Mar; 38(3):133-40. PubMed ID: 18276097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Nagy E; Dowzicky MJ
    Scand J Infect Dis; 2010; 42(1):33-8. PubMed ID: 19883155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of tigecycline and comparators against a European collection of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2010-2016.
    Rodloff AC; Dowzicky MJ
    Anaerobe; 2018 Jun; 51():78-88. PubMed ID: 29679648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study.
    Turner PJ
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):273-9. PubMed ID: 16360551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008.
    Wang YF; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2010 Sep; 68(1):73-9. PubMed ID: 20727474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.
    Hawser SP; Bouchillon SK; Hackel M; Chen M; Kim EC
    Int J Antimicrob Agents; 2012 Jun; 39(6):490-5. PubMed ID: 22534507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
    Morfin-Otero R; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.
    Fritsche TR; Jones RN
    Int J Antimicrob Agents; 2004 Dec; 24(6):567-71. PubMed ID: 15555879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
    Hoban DJ; Reinert RR; Bouchillon SK; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 May; 14():27. PubMed ID: 25958201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empiric treatment options in the management of complicated intra-abdominal infections.
    Weigelt JA
    Cleve Clin J Med; 2007 Aug; 74 Suppl 4():S29-37. PubMed ID: 17847176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates].
    Nayman Alpat S; Aybey AD; Akşit F; Ozgüneş I; Kiremitçi A; Usluer G
    Mikrobiyol Bul; 2010 Oct; 44(4):641-5. PubMed ID: 21063976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.
    Kehl SC; Dowzicky MJ
    J Clin Microbiol; 2015 Apr; 53(4):1286-93. PubMed ID: 25653413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR; Dowzicky MJ
    Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.